Prospector
Profile
1108-07
|
| |
| Pluristem Life Systems, Inc. |
NAICS |
541710 |
| MATAM Advanced Technology Park
Haifa, Israel 31905 |
Description |
Biotechnology |
| 011-972-4-850-1080 |
Employees |
17 |
| http://www.pluristem.com/ |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-8.4280 |
| |
Assets |
(mil) |
6.7260 |
| |
Liability |
(mil) |
0.8300 |
| |
(for the year ended 2007-06-30) |
| |
|
Category:
Audit Concerns
|
| |
|
Event:
Kost Forer Gabbay & Kasierer raised substantial doubt about the ability of Pluristem Life Systems, Inc. to continue as a going concern after auditing its financial statements. The auditor points out that the Company has not yet generated revenues from its operations and is dependent on external sources for financing its operations. The Company has suffered recurring losses from operations and has accumulated losses of approximately $15,517,980 since inception.
|
| |
|
Intellectual Property:
The Company's patented technology, entitled “Method and Apparatus for Maintenance and Production of Hematopoietic Stem Cells and/or Progenitor Cells," is patented in Australia, Russia, New Zealand and South Africa and has patents pending in the U.S., Canada, Japan, Mexico and elsewhere. The Company also has a patent for its technology entitled “Method Of Producing Undifferentiated Hemopoietic Stem Cells Using A Stationary Phase Plug-Flow Bioreactor.” The Company filed patent applications for its “Three Dimensional Scaffolds For Ex-Vivo Expansion Of Stem Cells And Their Transplantion.” The Company has filed one provisional patent with the US Patent and Trademark Office for a new procedure for expanding hematopoeitic stem cells and early progenitor cells from cord blood from non selected mono-nuclear cells of the cord blood. [SEC Filing 10-KSB 09-05-07]
|
| |
|
Description:
The Company is dedicated to the commercialization of cell therapy to treat severe blood, cardiovascular, autoimmune, and other disorders.
|
| |
|
Officers:
Zami Aberman (Pres., CEO & Dir.); Yaky Yanay (CFO & Sec.); Ora Burger (VP); Dr. Shai Meretizki (Chief Technology Officer); Doron Shorrer (Dir.); Hava Meretzki (Dir.); Isaac Braun (Dir.); Israel Ben-Yoram (Dir.); Mark Germain (Dir.)
|
| |
|
Auditor:
Kost Forer Gabbay & Kasierer
|
| |
|
Securities:
Common Stock-Symbol PLRS.OB; OTC BB;
1,156,195,593 common shares outstanding as of August 28, 2007.
|
| |
| |
| |
| return to main page |
